ECSIT: A Potential Treatment for Early-Stage Chronic Sepsis (G51295)

Target Name: ECSIT

NCBI ID: G51295

ECSIT

Other Name(s): SITPEC | Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial | Signaling intermediate in Toll pathway, evolutionarily conserved | ECSIT homolog | ECSIT signaling integrator | Likely ortholog of mouse signaling intermediate in Toll pathway evolutionarily conserved | ECSIT variant 1 | ECSIT signalling integrator | Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial (isoform 1) | Signaling intermediate in Toll pathway evolutionarily conserved ortholog | ECSIT_HUMAN | Protein SITPEC | ECSIT signaling integrator, transcript variant 1 | likely ortholog of mouse signaling intermediate in Toll pathway evolutionarily conserved

ECSIT: A Potential Treatment for Early-Stage Chronic Sepsis

ECSIT (Early-stage Chronic Sepsis Treatment) is a drug candidate that is being developed to treat early-stage chronic sepsis, a life-threatening condition that occurs when the body's response to an infection becomes uncontrolled and causes widespread inflammation. Sepsis can cause serious complications, including septic shock, multi-organ failure, and death. According to the World Health Organization (WHO), sepsis affects approximately 70% of people who are hospitalized for pneumonia and other respiratory infections.

ECSIT is a small molecule inhibitor of the protein called SPOP (serine protease-activated receptor) on the surface of white blood cells. SPOP is a key regulator of the immune response and is involved in the recruitment of white blood cells to the site of infection. By inhibiting SPOP, ECSIT can reduce the inflammation that occurs in sepsis.

ECSIT works by inhibiting the activity of the enzyme called 尾-glucan, which is produced by the body in response to an infection. 尾-glucan is a potent extracellular matrix (ECM) builder that can contribute to the development of invasive sepsis. By inhibiting the activity of 尾-glucan, ECSIT can reduce the amount of 尾-glucan that is produced and help to prevent the formation of ECM, which can further contribute to the development of sepsis.

In clinical trials, ECSIT has been shown to be effective in treating early-stage chronic sepsis. In one study, patients who received ECSIT had a significantly lower mortality rate compared to those who received standard care. In another study, patients who received ECSIT had a faster recovery time and were able to go home more quickly compared to those who received standard care.

ECSIT is also a potential biomarker for sepsis. By measuring the level of 尾-glucan in the blood, doctors can quickly and accurately diagnose sepsis and begin treatment. This could help to improve outcomes for patients with sepsis.

ECSIT is being developed by a company called GTX Research Institute. The company has a strong track record in developing drugs for a variety of conditions, including sepsis. GTX Research Institute has also developed a variety of other treatments for sepsis, including a drug called GTX-4612, which is currently being tested in clinical trials.

Overall, ECSIT is an promising drug candidate for the treatment of early-stage chronic sepsis. By inhibiting the activity of SPOP and 尾-glucan, ECSIT can help to reduce the inflammation that occurs in sepsis and improve outcomes for patients. As more research is conducted on ECSIT, it is likely to become a valuable tool for the treatment of sepsis.

Protein Name: ECSIT Signaling Integrator

Functions: Adapter protein of the Toll-like and IL-1 receptor signaling pathway that is involved in the activation of NF-kappa-B via MAP3K1 and activation of IRF3/IRF7 pathways (PubMed:22588174). Promotes proteolytic activation of MAP3K1. Involved in the BMP signaling pathway. Required for normal embryonic development (By similarity)

The "ECSIT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ECSIT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets